Bio­gen CEO seeks 'aw­ful lot more col­lab­o­ra­tions' to beef up R&D as it launch­es post­par­tum de­pres­sion, Alzheimer's and ...

Last year
Deals
Pharma

For­ward Ther­a­peu­tics, the first biotech from Curie.Bio, rais­es $50M for oral small mol­e­cules in im­munol­o­gy

Last year
Financing
Startups

Ama­zon Prime mem­bers can now get One Med­ical mem­ber­ship at a dis­count

Last year
Health Tech

Gilead re­ports 'flat' Q3 rev­enues, cuts PhI­II Covid tri­al

Last year
R&D
Pharma

Bay­er un­veils big changes to busi­ness and head­count to ad­dress ‘not ac­cept­able’ per­for­mance

Last year
R&D
Pharma

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Last year
Startups
Cell/Gene Tx

Flag­ship Pi­o­neer­ing takes an­oth­er big step across the globe, plant­i­ng its biotech flag in Asia

Last year
Financing
Startups

Ac­tivist in­vestor El­liott buys $1B+ stake in Bio­Marin as CEO change nears

Last year
Pharma

Ei­sai eyes long game for Leqem­bi amid ‘dra­mat­i­cal­ly’ in­creas­ing pa­tient use

Last year
Pharma

Sen­ate con­firms Mon­i­ca Bertag­nol­li to lead NIH with bi­par­ti­san 62-36 vote

Last year
Pharma
FDA+

French au­thor­i­ties in­ves­ti­gate Sanofi over mar­ket ma­nip­u­la­tion, mis­lead­ing fi­nan­cial com­mu­ni­ca­tions

Last year
Pharma
Law

FTC chal­lenges more than 100 drug patents owned by Ab­b­Vie, As­traZeneca, Boehringer and sev­en oth­ers

Last year
FDA+
Law

Im­bria touts PhII suc­cess in hy­per­trophic car­diomy­opa­thy, adding fu­el to over­all ef­fi­ca­cy pro­file

Last year
R&D

Sage’s PPD drug to cost $15K; Ab­cam share­hold­ers vote 'yes' on Dana­her deal

Last year
News Briefing

Mar­ket­ingRx roundup: Sanofi, Re­gen­eron re­new Dupix­ent asth­ma ef­fort; Bausch Health bat­tles sea­son­al af­fec­tive ...

Last year
Pharma
Marketing

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Last year
Cell/Gene Tx
In Focus

Pfiz­er gath­ers Covid cam­paign 'i­con­s' Martha Stew­art, John Leg­end, Travis Kelce and more for lat­est boost­er push

Last year
Pharma
Marketing

WuXi XDC eyes IPO to boost ADC, bio­con­ju­gate man­u­fac­tur­ing foot­print

Last year
Financing
Manufacturing

Lil­ly backs Or­so­Bio's $60M Se­ries A for PhII tri­als in obe­si­ty and NASH

Last year
Financing
Startups

Gilead, Ar­cus’ PhII gas­troe­sophageal can­cer da­ta ar­gue for TIG­IT an­ti­body drug class po­ten­tial

Last year
R&D

Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Last year
R&D

Ap­plied­VR is bet­ting a new study could strength­en the case for in­sur­ance cov­er­age of its VR chron­ic pain treat­ment

Last year
Health Tech

No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

Last year
Deals
R&D

Ex­clu­sive: With back­ing of Ravens own­er, Black­bird launch­es with $100M to boost Bal­ti­more’s biotech scene

Last year
Financing
Startups
First page Previous page 249250251252253254255 Next page Last page
A service from the Financial Times